Part
01
of one
Part
01
What's the market for transdermal patches in India
Hello, and thank you for your request for the market size for transdermal patches in India. The short version is that despite exhaustively searching industry reports and databases, corporate websites, and trusted media sites, my colleagues and I determined that statistics on the market size for transdermal patches in India are published, but this information is only available as paid content. However, some general observations about global market size for transdermal patches, as well as trends specific to the Asia Pacific region (including India) were identified. Additionally, we have included some considerations for future research. Below you will find a deep dive of our findings.
METHODOLOGY
In order to determine the market size in India for transdermal patches, my colleagues and I reviewed industry reports and databases, corporate websites, and trusted media sites. We located a report entitled, "Global Transdermal Drug Delivery Market Analysis & Opportunity Outlook 2021." This report appears to provide the majority of information you requested, including market segmentation by region, growth motivators and challenges in the market, market size, market forecast, supply and demand, and geographical economic factors. Unfortunately, this report is available only as paid content, and information contained therein could not be publicly accessed. However, we were able to gather some useful data about the overall global market size for transdermal patches, and we identified some key trends for India, which is classified as a member of the Asia Pacific region. We have provided an overview of these findings below.
To determine if consumers in India are interested in topical patches and/or are already using transdermal patches, we reviewed industry reports and databases, as well as academic databases. We identified no academic research to quantify either consumer demand for transdermal patches or existing usage of these products in India. We then reviewed user forums and trusted media sites in an effort to locate survey results and/or user reviews of topical patches, which we could use to triangulate data for transdermal patch usage in India. We located no publicly available information on this topic, and perhaps more significantly, we did not identify any results available as paid content. The only information published on this topic was an outdated article from 2012, which indicated that transdermal patch usage was virtually non-existent in India at that time, due to challenges in the market, which are discussed in more detail below. This finding, along with an overall lack of published information on rates of transdermal patch usage in India, suggest this topic has simply not been researched.
With regard to price points for transdermal patches, we did not locate any published information about consumer preferences, possibly due to the same lack of readily available information on this topic. However, we reviewed two Indian online pharmaceutical sales databases, Drugs Update and MedIndia, to gain perspective on the types of transdermal patches currently available in India and average prices, which we have included below.
GLOBAL MARKET FOR TRANSDERMAL PATCHES
Although the majority of content available in the report, "Global Transdermal Drug Delivery Market Analysis & Opportunity Outlook 2021," is available only as paid content, my colleagues and I located a number of websites that published brief summaries and key statistics from this report that allowed us to determine some information about the global market for transdermal patches.
Our findings revealed that there are four types of transdermal patches currently marketed by pharmaceutical companies: membrane permeation controlled systems, matrix diffusion-controlled systems, adhesive dispersion-type systems, and microreservoir type or microsealed dissolution controlled systems. Of these four segments of the market, the matrix delivery system represents the largest share in the overall transdermal patch market, due to the advantages associated with the controlled release delivery mechanism.
Major advantages for transdermal patches include the avoidance of gastrointestinal interference that is associated with traditional oral administration, reduced pharmaceutical dosage needs due to the shortened metabolic absorption rate through the skin, more consistent dosage rates, the ability to deliver multi-day therapy in one application, and the ease of discontinuation of the medication. The primary challenge associated with transdermal patches includes the high cost of the products relative to oral and/or injected medications, although our findings revealed that in India specifically, there is a mistaken cultural concern that the use of opioid transdermal patches will increase the likelihood of addiction. Although this article is outdated, the finding may still hold some significance in this market.
The global market size for the transdermal patch industry has expanded rapidly. Estimated at $22 billion in 2010, the market expanded to $32 billion by 2015, yielding a compound annual growth rate of 8.0%. From 2017 to 2022, the global market size is expected to increase by 4.2%. The global market is divided into five segments: North America, Europe, Asia Pacific, Latin America, and the Middle East/Africa. In 2015, the North American market was the largest of the five segments, garnering 50% of total market share, followed by the European segment. Although we could not determine a publicly available percentage for the Asia Pacific market share, our findings revealed that the Asia Pacific region is the third largest segment in the global transdermal patch market.
Mylan Pharmaceuticals is the most prominent player in the global transdermal patch market, although other key players include Novartis AG, Johnson & Johnson, Boehringer Ingelheim GmbH, Biogel Technology, Transdermal Technologies, Skyepharma, Watson Pharmaceuticals, 3M Company, Noven Pharmaceuticals, 4P Therapeutics, Transdermal Corporation, and Echo Therapeutics. Transdermal drugs are classified into five categories: Cardiovascular, Central Nervous System, Hormone, Pain Management, and "Others." Our findings revealed that popular transdermal patches in the "others" category include tobacco cessation products. Distribution channels for transdermal patches include hospital pharmacies, online pharmacies, independent local pharmacies, and drug stores, although the availability of these medications at each channel vary by country, based on individual pharmaceutical and licensing laws.
TRENDS IN THE ASIA PACIFIC SECTOR
India is classified as a member of the Asia Pacific sector, and our findings indicate that while the Asia Pacific region only holds the third largest share of the global market, it is the fastest growing segment. This trend is the result of stable research and development in more developed countries, as well as existing widespread adoption of transdermal drug delivery systems there. On the contrary, the Asia Pacific sector is experiencing rising consumer demand for innovative treatments at affordable costs, resulting in increased interest in transdermal patches. Additionally, governments in the Asia Pacific sector have recently invested in improved technology and healthcare infrastructure, which are also supporting increased growth in the market.
The Asia Pacific sector is expected to demonstrate the fastest compound annual growth rate of any sector in the global market from 2017 to 2015 at 12.0%. In addition to the previously mentioned factors motivating growth, the impact of medical tourism is expected to be significant in this region. As medical tourism within these countries becomes more common, healthcare infrastructure is expanding, resulting in increased construction of renowned medical facilities, decreases in costs for medical procedures, and higher demand for less invasive pharmaceutical treatment options for chronic diseases. The underlying conditions motivating transdermal patch delivery include many increasingly common chronic diseases, such as cardiovascular diseases, cancer, and diabetes.
Our research also revealed that there is increased interest in the use of transdermal patches within the Asia Pacific sector, but usage rates vary considerably based on the type of medication. For example, transdermal tobacco cessation products have only been produced by Indian manufacturers since 2015, although they have been prominent in the North American and European sectors for significantly longer. In 2017, Rusan Pharmaceuticals, which released the first Indian-manufactured product, 2baconil, has only recently announced the release of a second tobacco cessation product. On the other hand, as we will discuss in greater detail below, there are numerous brand-name and generic products available to treat pain, such as the opioid painkiller, Fentanyl. Similarly, our research revealed that many market analyses focus on the global usage of specific transdermal products, such as scopolamine, which was released in 1979 to treat motion sickness.
POPULAR PRODUCTS AND PRICES
Although we were unable to locate any published statistics on current transdermal patch usage in India, consumer demand and attitudes towards topical patches, or price points of interest for consumers, we did identify some common transdermal medications currently used in India. We researched drug prices on Drugs Update and MedIndia to provide perspective on the current market in India.
Our findings suggest that transdermal opioid painkillers are popular in India, with three different manufacturers producing multiple doses of brand-name or generic Fentanyl products. Johnson & Johnson produces Durogesic at three strengths, with prices noted in parentheses per patch (in Indian rupees): 12 mcg (₹266), 25 mcg (₹495), and 50 mcg (₹953). Rusan produces Fenstud in two doses: 3 mg (₹ 415) and 6 mg (₹795). Finally, Dr. Reddy's produces one product, Finrid, at two doses: 25 mcg (₹320) and 50 mcg (₹640).
Non-steroidal anti-inflammatory drugs (NSAID's) are also popular in India. Indocour produces Reylonketo, a 30 mg transdermal patch available for ₹99 for three patches. Emcure offers Kelopatch, a 30 mg transdermal patch available for ₹19, and Proxym in the form of a 40 mg patch for ₹49. Zydus Codila produces Nupatch in two doses: 100 mg/50 cm (₹40.19) and 200 mg/50 cm (₹53.22).
Finally, there are various other transdermal patches available in India. In addition to the previously mentioned tobacco cessation products, Novartis India produces Exelon for the treatment of Alzheimer's Disease, although we could not identify pricing information for this product. Emcure produces ETS Patch, which is a hormonal estradiol treatment, for ₹49 for a 1.8 mg patch.
CONSIDERATIONS FOR FUTURE RESEARCH
Unfortunately, we located very little publicly available information on the requested topics. However, it may be helpful to review the summary of findings produced in the report, "Global Transdermal Drug Delivery Market Analysis & Opportunity Outlook 2021," to determine if purchasing this document will provide you with the information you require.
CONCLUSION
In summary, despite exhaustive research, my colleagues and I determined that statistics on the market size for transdermal patches in India are published, but this information is only available as paid content. However, we did determine that the global market size for the transdermal patch industry was estimated at $22 billion in 2010, and the market expanded to $32 billion by 2015. From 2017 to 2022, the global market size is expected to increase by 4.2%. The Asia Pacific sector, which includes India, is expected to demonstrate the fastest compound annual growth rate of any sector in the global transdermal drug market from 2017 to 2025 at 12.0%.
Thank you for your request, and if you would like additional information on this or another topic, please do not hesitate to ask Wonder!